116 related articles for article (PubMed ID: 14747425)
1. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
2. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Lefèvre G; Duval M; Gauron S; Brookman LJ; Rolan PE; Morris TM; Piraino AJ; Morgan JM; Palmisano M; Close P
Clin Pharmacol Ther; 1997 Jul; 62(1):50-9. PubMed ID: 9246019
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
[TBL] [Abstract][Full Text] [Related]
7. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
13. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
16. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
17. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease.
Brand P; Meyer T; Weuthen T; Timmer W; Berkel E; Wallenstein G; Scheuch G
J Clin Pharmacol; 2007 Oct; 47(10):1335-41. PubMed ID: 17625157
[TBL] [Abstract][Full Text] [Related]
18. Accidental overdose of tiotropium in a patient with atrial fibrillation.
Gregory MD; Mersfelder TL; Jamieson T
Ann Pharmacother; 2010 Feb; 44(2):391-3. PubMed ID: 20118141
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
20. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
